Radioligand Therapy Targets in Lymphoma
We screened every cell-surface protein with tumor immunohistochemistry data in lymphoma (including Hodgkin and non-Hodgkin lymphoma). 3,490 show detectable protein staining. Established and emerging radioligand targets expressed in lymphoma include CD20 (MS4A1), CD45 (PTPRC), CD19 and c-MET (MET). Below, we rank every candidate by tumor expression, internalization and clinical maturity.
Need a shortlist for your own lymphoma program? Rank every candidate against your isotope, organ-dose limits and novelty bar.
Rank lymphoma targets freeEstablished and emerging radioligand targets in lymphoma
Targets already pursued with radioligands or other targeted modalities that show protein expression in lymphoma:
| Target | IHC in lymphoma | % positive | Internalizes |
|---|---|---|---|
| CD20 (MS4A1) | High (0.97) | 100% | uncertain |
| CD45 (PTPRC) | High (0.72) | 83% | no |
| CD19 | High (0.64) | 73% | — |
| c-MET (MET) | Medium (0.47) | 92% | yes |
| HER3 (ERBB3) | Medium (0.31) | 67% | yes |
| STEAP2 | Medium (0.31) | 58% | — |
| TMEFF2 | Medium (0.31) | 50% | — |
| CD22 | Medium (0.31) | 58% | — |
| CD33 | Low (0.19) | 33% | — |
| SSTR2 | Low (0.14) | 42% | yes |
| ITGAV | Low (0.14) | 33% | — |
| B7-H3 (CD276) | Low (0.08) | 25% | — |
| CD38 | Low (0.08) | 8% | — |
| Nectin-4 (NECTIN4) | Low (0.03) | 9% | no |
Top cell-surface targets for lymphoma radioligand therapy
A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.
| # | Target | IHC in lymphoma | % positive | Internalizes | Clinical stage |
|---|---|---|---|---|---|
| 1 | S1PR1 sphingosine-1-phosphate receptor 1 | High (0.58) | 92% | yes | FDA-Approved |
| 2 | IGF1R insulin like growth factor 1 receptor | High (0.72) | 100% | yes | FDA-Approved |
| 3 | AMFR autocrine motility factor receptor | High (1.00) | 100% | yes | Discovery |
| 4 | GPR139 G protein-coupled receptor 139 | High (0.97) | 100% | yes | Discovery |
| 5 | c-MET (MET) MET proto-oncogene, receptor tyrosine kinase | Medium (0.47) | 92% | yes | FDA-Approved |
| 6 | PTPN13 protein tyrosine phosphatase non-receptor type 13 | High (0.83) | 92% | yes | Discovery |
| 7 | EPHB2 EPH receptor B2 | High (0.64) | 100% | uncertain | FDA-Approved |
| 8 | BRAF B-Raf proto-oncogene, serine/threonine kinase | High (0.97) | 100% | — | FDA-Approved |
| 9 | NR3C2 nuclear receptor subfamily 3 group C member 2 | High (0.67) | 100% | uncertain | FDA-Approved |
| 10 | RNF43 ring finger protein 43 | High (1.00) | 100% | — | Discovery |
| 11 | CD20 (MS4A1) membrane spanning 4-domains A1 | High (0.97) | 100% | uncertain | FDA-Approved |
| 12 | TNFRSF13C TNF receptor superfamily member 13C | High (0.94) | 100% | uncertain | Clinical |
| 13 | KCNG1 potassium voltage-gated channel modifier subfamily G member 1 | High (0.75) | 100% | — | FDA-Approved |
| 14 | GRK6 G protein-coupled receptor kinase 6 | High (0.75) | 100% | yes | Discovery |
| 15 | HMGA1 high mobility group AT-hook 1 | High (0.97) | 100% | — | Discovery |
| 16 | APH1A aph-1A gamma-secretase subunit | High (0.94) | 100% | — | FDA-Approved |
| 17 | BTK Bruton tyrosine kinase | High (0.92) | 100% | — | FDA-Approved |
| 18 | M6PR mannose-6-phosphate receptor, cation dependent | High (0.73) | 100% | yes | Discovery |
| 19 | LSR lipolysis stimulated lipoprotein receptor | High (0.73) | 100% | yes | Discovery |
| 20 | PLCG2 phospholipase C gamma 2 | High (0.97) | 100% | — | Discovery |
| 21 | GPER1 G protein-coupled estrogen receptor 1 | High (0.78) | 83% | yes | Discovery |
| 22 | BIN1 bridging integrator 1 | High (0.97) | 100% | — | Discovery |
| 23 | LCK LCK proto-oncogene, Src family tyrosine kinase | High (0.89) | 100% | — | FDA-Approved |
| 24 | TRIP11 thyroid hormone receptor interactor 11 | High (1.00) | 100% | uncertain | Discovery |
| 25 | PRKCD protein kinase C delta | High (0.97) | 100% | — | Clinical |
Internalizing receptors in lymphoma
Targets expressed in lymphoma that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:
S1PR1 · IGF1R · AMFR · GPR139 · c-MET (MET) · PTPN13 · GRK6 · M6PR · LSR · GPER1 · PTPN22 · GRK2
Lymphoma targets already in clinical development
Targets with a clinical-stage drug program (any modality) that are also expressed in lymphoma. Clinical precedent lowers development risk but usually means more competition:
S1PR1 · IGF1R · c-MET (MET) · EPHB2 · BRAF · NR3C2 · CD20 (MS4A1) · TNFRSF13C · KCNG1 · APH1A · BTK · LCK
How these lymphoma targets are ranked
Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in lymphoma, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.
Rank lymphoma targets against your own criteria: isotope, organ limits, novelty.
Run a free lymphoma analysisRadioligand therapy targets in other cancers
- Prostate Cancer
- Neuroendocrine Tumors
- Lung Cancer
- Pancreatic Cancer
- Breast Cancer
- Ovarian Cancer
- Colorectal Cancer
- Kidney Cancer
- Bladder Cancer
- Gastric Cancer
- Liver Cancer
- Glioma
- Melanoma
- Head and Neck Cancer
- Thyroid Cancer
- Cervical Cancer
- Endometrial Cancer
- Skin Cancer
- Testicular Cancer
Data sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.